Foghorn Therapeutics Inc (FHTX) — Cash Flow Reinvestment Rate

Latest as of March 2022: 0.59x

Foghorn Therapeutics Inc (FHTX) has a Cash Flow Reinvestment Rate of 0.59x as of March 2022, reinvesting $159.41 Million (capex $247.00K plus investments $-159.16 Million) from operating cash flow of $271.53 Million. See cash generation quality of Foghorn Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.59x
(Capex + Investments) / Operating CF

Total Reinvested

$159.41 Million
Capex + Investments

Operating Cash Flow

$271.53 Million
USD

Capital Expenditures

$247.00K
USD

Foghorn Therapeutics Inc Cash Flow Reinvestment Rate (2022–2022)

Historical reinvestment intensity for Foghorn Therapeutics Inc across 1 annual periods. For the full cash flow conversion analysis, see Foghorn Therapeutics Inc operating cash flow efficiency.

Annual Cash Flow Reinvestment Rate for Foghorn Therapeutics Inc (2022–2022)

Year-by-year capital reinvestment analysis for Foghorn Therapeutics Inc. See Foghorn Therapeutics Inc (FHTX) flexibility index to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2022 1.26x $244.32 Million $193.61 Million $1.21 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow